Print（PDF/169KB） Jan. 31, 2023 Finances

Notice Concerning Finance Costs

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that it has recorded finance costs for the three months ended December 31, 2022 as follows.

1. Details of Finance Costs

The Company has recorded a foreign exchange loss of 31,214 million yen under finance costs for the three months ended December 31, 2022 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of assets denominated in foreign currencies.
In addition, foreign exchange gains for the nine months ended December 31, 2022 totaled 18,441 million yen, because financial income (foreign exchange gain) of 49,655 million yen was recorded in the six months ended September 30, 2022.

2. Future Outlook

Regarding the impact of the above finance income on the results of the Company operations, please refer to the “Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2023 [IFRS]” announced today. In addition, although the amount of foreign exchange gains will fluctuate due to future exchange rates, the Company has factored a certain amount of foreign exchange gains into the revised financial forecasts announced today.